


Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Original) A compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof



wherein

$X$  represents an oxygen atom or a group  $NR^4$  or  $CH_2$ ;

$Y$  represents  $NH$  or  $N$ -methyl;

$Z^1$  and  $Z^2$  each independently represent an oxygen or sulphur atom, provided that at least one of  $Z^1$  and  $Z^2$  represents an oxygen atom;

Either  $R^1$  represents hydrogen or a group selected from  $C_1$ - $C_6$  alkyl and a saturated or unsaturated 3- to 10-membered ring system which may comprise at least one ring heteroatom selected from nitrogen, oxygen and sulphur, each group being optionally substituted with at least one substituent selected from halogen, hydroxyl, cyano, carboxyl,  $-NR^5R^6$ ,  $-CONR^7R^8$ ,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkoxy,  $C_1$ - $C_6$  alkylcarbonyl(oxy),  $-S(O)_mC_1$ - $C_6$  alkyl where  $m$  is 0, 1 or 2,  $C_1$ - $C_6$  alkylsulphonylamino,  $C_1$ - $C_6$  alkoxy carbonyl(amino), benzyloxy and a saturated or unsaturated 5- to 6-membered ring which may comprise at least one ring heteroatom selected

from nitrogen, oxygen and sulphur, the ring in turn being optionally substituted with at least one substituent selected from halogen, hydroxyl, oxo, carboxyl, cyano, C<sub>1</sub>-C<sub>6</sub> alkyl,

C<sub>1</sub>-C<sub>6</sub> alkoxy carbonyl and C<sub>1</sub>-C<sub>6</sub> hydroxyalkyl,

R<sup>2</sup> represents hydrogen or C<sub>1</sub>-C<sub>6</sub> alkyl, and

R<sup>3</sup> represents hydrogen or C<sub>1</sub>-C<sub>6</sub> alkyl,

or

R<sup>1</sup> and R<sup>2</sup> together with the carbon atoms to which they are attached form a saturated 5- to 6-membered ring optionally comprising a ring heteroatom selected from nitrogen, oxygen and sulphur, and R<sup>3</sup> is as defined above,

or

R<sup>2</sup> and R<sup>3</sup> together with the carbon atom to which they are attached form a saturated 5- to 6-membered ring optionally comprising a ring heteroatom selected from nitrogen, oxygen and sulphur, and R<sup>1</sup> is as defined above;

R<sup>4</sup> represents hydrogen or C<sub>1</sub>-C<sub>6</sub> alkyl;


R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup> and R<sup>8</sup> each independently represent hydrogen or C<sub>1</sub>-C<sub>6</sub> alkyl optionally substituted by at least one substituent selected from hydroxyl, halogen and C<sub>1</sub>-C<sub>6</sub> alkoxy;

L represents -CH<sub>2</sub>C(O)- or -C(O)CH<sub>2</sub>-, or

L represents a C<sub>2</sub>-C<sub>6</sub> alkyl or C<sub>2</sub>-C<sub>6</sub> alkynyl group optionally interrupted or terminated by at least one moiety selected from O, NH, S, SO, SO<sub>2</sub> and C(O), or L represents a C<sub>3</sub>-C<sub>6</sub> cycloalkyl, methylC<sub>3</sub>-C<sub>6</sub> cycloalkyl or C<sub>3</sub>-C<sub>6</sub> cycloalkylmethyl group, each of the recited groups being optionally substituted with at least one substituent selected from hydroxyl, halogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy and C<sub>1</sub>-C<sub>4</sub> haloalkoxy, or

L represents a C<sub>3</sub>-C<sub>4</sub> alkylene chain, the ends of which are attached to adjacent ring carbon atoms in the 5- to 10-membered ring system of G<sup>2</sup> to form a ring;

G<sup>2</sup> represents a saturated or unsaturated 5- to 10-membered ring system which may comprise at least one ring heteroatom selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted with at least one substituent selected from halogen, hydroxyl, cyano, nitro, C<sub>1</sub>-C<sub>6</sub> alkyl (optionally substituted by one or more of cyano, halogen, hydroxyl and methoxy), C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>1</sub>-C<sub>6</sub> alkoxy (optionally substituted by one or more halogen atoms), -S(O)<sub>n</sub>C<sub>1</sub>-C<sub>6</sub> alkyl where n is 0, 1 or 2, C<sub>1</sub>-C<sub>6</sub> alkylcarbonyl(amino), C<sub>1</sub>-C<sub>6</sub> alkylcarbonyloxy, phenyl, benzyloxy, -NR<sup>9</sup>R<sup>10</sup> and a group of formula



R<sup>9</sup> and R<sup>10</sup> each independently represent hydrogen or C<sub>1</sub>-C<sub>6</sub> alkyl optionally substituted by at least one substituent selected from hydroxyl, halogen and C<sub>1</sub>-C<sub>6</sub> alkoxy;

M represents a bond or -O-, -S-, -C≡C-, -CH<sub>2</sub>O- or -OCH<sub>2</sub>-;

G<sup>3</sup> represents an unsaturated 5- to 10-membered ring system which may comprise at least one ring heteroatom selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted with at least one substituent selected from halogen, hydroxyl, cyano, nitro, C<sub>1</sub>-C<sub>6</sub> alkyl (optionally substituted by one or more of cyano, halogen, hydroxyl and methoxy), C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>1</sub>-C<sub>6</sub> alkoxy (optionally substituted by one or more halogen atoms), -S(O)<sub>t</sub>C<sub>1</sub>-C<sub>6</sub> alkyl where t is 0, 1 or 2, C<sub>1</sub>-C<sub>6</sub> alkylcarbonyl(amino), C<sub>1</sub>-C<sub>6</sub> alkylcarbonyloxy, phenyl, benzyloxy and -NR<sup>11</sup>R<sup>12</sup>; and

$R^{11}$  and  $R^{12}$  each independently represent hydrogen or  $C_1$ - $C_6$  alkyl optionally substituted by at least one substituent selected from hydroxyl, halogen and  $C_1$ - $C_6$  alkoxy.

2. (Original) A compound according to claim 1, wherein X represents a group  $NR^4$ .
3. (Original) A compound according to claim 2, wherein  $R^4$  represents hydrogen.
4. (Currently amended) A compound according to ~~any one of claims 1 to 3~~claim 1, wherein Y represents NH.
5. (Currently amended) A compound according to ~~any one of the preceding claims~~claim 1, wherein  $Z^1$  and  $Z^2$  both represent an oxygen atom.
6. (Currently amended) A compound according to ~~any one of the preceding claims~~claim 1, wherein L represents a  $C_2$ - $C_4$  alkyl group optionally interrupted or terminated by one or two moieties independently selected from O, NH, S, SO,  $SO_2$  and C(O), or L represents a  $C_3$ - $C_6$  cycloalkyl, methyl- $C_3$ - $C_6$  cycloalkyl or  $C_3$ - $C_6$  cycloalkylmethyl group, each of the recited groups being optionally substituted with one or two substituents independently selected from hydroxyl, halogen,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  haloalkyl,  $C_1$ - $C_4$  alkoxy and  $C_1$ - $C_4$  haloalkoxy.
7. (Currently amended) A compound according to ~~any one of claims 1 to 5~~claim 1, wherein L represents a  $C_3$ - $C_4$  alkylene chain, the ends of which are attached to adjacent ring carbon atoms in the 5- to 10-membered ring system of  $G^2$  to form a ring.

8. (Original) A compound according to claim 7, wherein the 5- to 10-membered ring system of  $G^2$  is phenyl.
9. (Currently amended) A compound according to ~~any one of claims 1 to 7~~claim 1, wherein, in  $G^2$ , the saturated or unsaturated 5- to 10-membered ring system is selected from cyclopentyl, cyclohexyl, bicyclo[2.2.1]heptyl, cyclopentenyl, cyclohexenyl, phenyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, diazabicyclo[2.2.1]hept-2-yl, naphthyl, benzofuranyl, benzothienyl, benzodioxolyl, quinolinyl, 2,3-dihydrobenzofuranyl, tetrahydropyranyl, pyrazolyl, pyrazinyl, thiazolidinyl, indanyl, thienyl, isoxazolyl, pyridazinyl, thiadiazolyl, pyrrolyl, furanyl, thiazolyl, indolyl, imidazolyl, pyrimidinyl, benzimidazolyl, triazolyl, tetrazolyl and pyridinyl.
10. (Currently amended) A compound according to ~~any one of the preceding claims~~claim 1, wherein, in  $G^3$ , the unsaturated 5- to 10-membered ring system is selected from cyclopentenyl, cyclohexenyl, phenyl, naphthyl, benzofuranyl, benzothienyl, benzodioxolyl, quinolinyl, 2,3-dihydrobenzofuranyl, pyrazolyl, pyrazinyl, thiazolidinyl, indanyl, thienyl, isoxazolyl, pyridazinyl, thiadiazolyl, pyrrolyl, furanyl, thiazolyl, indolyl, imidazolyl, pyrimidinyl, benzimidazolyl, triazolyl, tetrazolyl and pyridinyl.
11. (Original) A compound according to claim 1 which is selected from the group consisting of:
- 2-(2,5-Dioxoimidazolidin-4-yl)-*N*-[2-(4'-fluoro-biphenyl-4-yl)-ethyl]-acetamide,
  - N*-[2-(4'-Cyano-biphenyl-4-yl)-ethyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,
  - 2-(2,5-Dioxoimidazolidin-4-yl)-*N*-(2-phenyl-cyclopropyl)-acetamide,
  - N*-[2-(4-Chlorophenyl)ethyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,
  - N*-(2-Biphenyl-4-yl-ethyl)-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,

2-(2,5-Dioxoimidazolidin-4-yl)-*N*-[2-(7-methyl-1H-indol-3-yl)ethyl]-acetamide,  
2-(2,5-Dioxoimidazolidin-4-yl)-*N*-[2-(4-phenoxyphenyl)ethyl]-acetamide,  
2-(2,5-Dioxoimidazolidin-4-yl)-*N*-[2-(4-fluorophenyl)ethyl]-acetamide,  
*N*-[2-(4-Bromophenyl)ethyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,  
*N*-[2-(2,4-Dichlorophenyl)ethyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,  
*N*-[2-(3'-Chloro-biphenyl-4-yl)-ethyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,  
*N*-[2-(4'-Benzyloxy-biphenyl-4-yl)-ethyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,  
2-(2,5-Dioxoimidazolidin-4-yl)-*N*-[2-(4-thiophen-3-yl-phenyl)ethyl]-acetamide,  
2-(2,5-Dioxoimidazolidin-4-yl)-*N*-[2-(4-thiophen-2-yl-phenyl)ethyl]-acetamide,  
*N*-[2-(4'-Chloro-biphenyl-4-yl)-ethyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,  
2-(2,5-Dioxoimidazolidin-4-yl)-*N*-[2-(4'-methylsulfanyl-biphenyl-4-yl)ethyl]-acetamide,  
2-(2,5-Dioxoimidazolidin-4-yl)-*N*-[2-(3'-nitro-biphenyl-4-yl)ethyl]-acetamide,  
2-(2,5-Dioxoimidazolidin-4-yl)-*N*-[2-(4'-methyl-biphenyl-4-yl)ethyl]-acetamide,  
*N*-[2-(3'-Acetylamino-biphenyl-4-yl)ethyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,  
2-(2,5-Dioxoimidazolidin-4-yl)-*N*-[2-(4-naphthalen-2-yl-phenyl)ethyl]-acetamide,  
*N*-[2-(3',5'-Dichloro-biphenyl-4-yl)ethyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,  
2-(2,5-Dioxoimidazolidin-4-yl)-*N*-[2-(3'-methyl-biphenyl-4-yl)ethyl]-acetamide,  
*N*-[2-(4-Benzofuran-2-yl-phenyl)ethyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,  
2-(2,5-Dioxoimidazolidin-4-yl)-*N*-[2-(3'-methoxy-biphenyl-4-yl)ethyl]-acetamide,  
2-(2,5-Dioxoimidazolidin-4-yl)-*N*-(2-[1,1';4',1'']terphenyl-4-ylethyl)-acetamide,  
*N*-[2-(4'-Acetyl-biphenyl-4-yl)ethyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,  
*N*-[2-(4-Benzo[b]thiophen-2-yl-phenyl)ethyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,  
*N*-[2-(4'-Cyanomethyl-biphenyl-4-yl)ethyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,  
2-(2,5-Dioxoimidazolidin-4-yl)-*N*-[2-(4-pyridin-3-yl-phenyl)ethyl]-acetamide,  
2-(2,5-Dioxoimidazolidin-4-yl)-*N*-{2-[4-(1H-pyrrol-2-yl)phenyl]ethyl}-acetamide,  
2-(2,5-Dioxoimidazolidin-4-yl)-*N*-[2-(4-furan-3-yl-phenyl)ethyl]-acetamide,  
2-(2,5-Dioxoimidazolidin-4-yl)-*N*-[2-(4-furan-2-yl-phenyl)ethyl]-acetamide,  
2-(2,5-Dioxoimidazolidin-4-yl)-*N*-(2-thiophen-2-yl-ethyl)-acetamide,

*N*-[2-(4-*tert*-Butylphenyl)ethyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,  
*N*-[2-(4-Chlorophenyl)-1-methylethyl]-2-(2,5-dioxoimidazolidin-4-yl)acetamide,  
*N*-{[1-(4-Chlorophenyl)cyclopropyl]methyl}-2-(2,5-dioxoimidazolidin-4-yl)acetamide,  
*N*-2,3-Dihydro-1H-inden-2-yl-2-(2,5-dioxoimidazolidin-4-yl)acetamide,  
*N*-[2-(4-Chlorophenyl)ethyl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)acetamide,  
*N*-[2-(4-Chlorophenyl)propyl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)acetamide,  
*N*-[2-(4'-Cyano-1,1'-biphenyl-4-yl)ethyl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)acetamide,  
*N*-[2-(4'-Fluoro-1,1'-biphenyl-4-yl)ethyl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)acetamide,  
2-(2,5-Dioxoimidazolidin-4-yl)-*N*-[2-(4'-fluoro-1,1'-biphenyl-4-yl)propyl]-acetamide,  
*N*-[(1*S*,2*R*)-2-(4'-Methoxybiphenyl-4-yl)cyclopropyl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,  
*N*-[(1*S*,2*R*)-2-(4'-Cyanobiphenyl-4-yl)cyclopropyl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,  
*N*-[(1*S*,2*R*)-2-(4'-Acetylbiphenyl-4-yl)cyclopropyl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,  
*N*-{[(1*S*,2*R*)-2-[4'-(Acetylamino)biphenyl-4-yl]cyclopropyl}-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,  
*N*-[2-(4'-Cyanobiphenyl-4-yl)propyl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,  
2-(2,5-Dioxoimidazolidin-4-yl)-*N*-[2-(3'-methoxybiphenyl-4-yl)ethyl]-acetamide,  
*N*-[2-(4'-Cyano-3'-methylbiphenyl-4-yl)propyl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,  
2-(2,5-Dioxoimidazolidin-4-yl)-*N*-methyl-*N*-(2-phenylethyl)-acetamide,  
*N*-[1-(4-Chlorophenyl)ethyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,  
2-(2,5-Dioxoimidazolidin-4-yl)-*N*-(2-hydroxy-1-methyl-2-phenylethyl)-acetamide,  
*N*-{2-[4-(1,3-Benzodioxol-5-yl)phenyl]propyl}-2-(2,5-dioxoimidazolidin-4-

yl)-acetamide,

2-(2,5-Dioxoimidazolidin-4-yl)-*N*-[2-(3'-methoxybiphenyl-4-yl)propyl]-acetamide,  
*N*-{2-[3'-(Acetylamino)biphenyl-4-yl]propyl}-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,  
*N*-[2-(3'-Acetylbiphenyl-4-yl)propyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,  
*N*-[2-(4'-Acetylbiphenyl-4-yl)propyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,  
*N*-{2-[4-(1-Benzothien-2-yl)phenyl]propyl}-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,  
*N*-[2-(3'-Cyanobiphenyl-4-yl)propyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,  
*N*-[2-(4'-Cyanobiphenyl-4-yl)propyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,  
2-(2,5-Dioxoimidazolidin-4-yl)-*N*-[2-(4'-fluoro-3'-methylbiphenyl-4-yl)propyl]-

acetamide,

2-(2,5-Dioxoimidazolidin-4-yl)-*N*-{2-[3'-(methylthio)biphenyl-4-yl]propyl}-acetamide,  
2-(2,5-Dioxoimidazolidin-4-yl)-*N*-{2-[4-(6-methoxypyridin-3-yl)phenyl]propyl}-

acetamide,

2-(2,5-Dioxoimidazolidin-4-yl)-*N*-[2-(4'-methoxy-3'-methylbiphenyl-4-yl)propyl]-

acetamide,

*N*-{2-[4-(2,3-Dihydro-1-benzofuran-5-yl)phenyl]propyl}-2-(2,5-dioxoimidazolidin-4-yl)-

acetamide,

2-(2,5-Dioxoimidazolidin-4-yl)-*N*-{2-[3'-(trifluoromethoxy)biphenyl-4-yl]propyl}-

acetamide,

*N*-[2-(3',4'-Dimethoxybiphenyl-4-yl)propyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,

2-(2,5-Dioxoimidazolidin-4-yl)-*N*-[2-(4-quinolin-3-ylphenyl)propyl]-acetamide,

*N*-[2-(4'-Cyano-3'-methylbiphenyl-4-yl)propyl]-2-(2,5-dioxoimidazolidin-4-yl)-

acetamide,

*N*-[5-(1,3-Benzodioxol-5-yl)-2,3-dihydro-1H-inden-2-yl]-2-(2,5-dioxoimidazolidin-4-yl)-

acetamide,

2-(2,5-Dioxoimidazolidin-4-yl)-*N*-[5-(3-methoxyphenyl)-2,3-dihydro-1H-inden-2-yl]-

acetamide,



*N*-{5-[3-(Acetylamino)phenyl]-2,3-dihydro-1H-inden-2-yl}-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,

*N*-[5-(3-Acetylphenyl)-2,3-dihydro-1H-inden-2-yl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,

*N*-[5-(4-Acetylphenyl)-2,3-dihydro-1H-inden-2-yl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,

*N*-[5-(1-Benzothien-2-yl)-2,3-dihydro-1H-inden-2-yl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,

*N*-[5-(3-Cyanophenyl)-2,3-dihydro-1H-inden-2-yl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,

*N*-[5-(4-Cyanophenyl)-2,3-dihydro-1H-inden-2-yl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,

2-(2,5-Dioxoimidazolidin-4-yl)-*N*-[5-(4-fluoro-3-methylphenyl)-2,3-dihydro-1H-inden-2-yl]-acetamide,

2-(2,5-Dioxoimidazolidin-4-yl)-*N*-{5-[3-(methylthio)phenyl]-2,3-dihydro-1H-inden-2-yl}-acetamide,

2-(2,5-Dioxoimidazolidin-4-yl)-*N*-[5-(6-methoxypyridin-3-yl)-2,3-dihydro-1H-inden-2-yl]-acetamide,

2-(2,5-Dioxoimidazolidin-4-yl)-*N*-[5-(4-methoxy-3-methylphenyl)-2,3-dihydro-1H-inden-2-yl]-acetamide,

*N*-[5-(2,3-Dihydro-1-benzofuran-5-yl)-2,3-dihydro-1H-inden-2-yl]-2-(2,5-dioxoimidazolidin-4-yl)acetamide,

*N*-[5-(3,4-Dimethoxyphenyl)-2,3-dihydro-1H-inden-2-yl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,

*N*-[2-(4'-Fluorobiphenyl-4-yl)propyl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,

*N*-{2-[4-(1,3-Benzodioxol-5-yl)phenyl]propyl}-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,

*N*-[2-(3'-Methoxybiphenyl-4-yl)propyl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,

*N*-{2-[4-(1-Benzothien-2-yl)phenyl]propyl}-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,

*N*-[2-(3'-Cyanobiphenyl-4-yl)propyl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,

*N*-[2-(4'-Fluoro-3'-methylbiphenyl-4-yl)propyl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,

2-(4-Methyl-2,5-dioxoimidazolidin-4-yl)-*N*-{2-[3'-(methylthio)biphenyl-4-yl]propyl}-acetamide,

*N*-{2-[4-(6-Methoxypyridin-3-yl)phenyl]propyl}-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,

*N*-[2-(4'-Methoxy-3'-methylbiphenyl-4-yl)propyl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,

*N*-{2-[4-(2,3-Dihydro-1-benzofuran-5-yl)phenyl]propyl}-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,

2-(4-Methyl-2,5-dioxoimidazolidin-4-yl)-*N*-{2-[3'-(trifluoromethoxy)biphenyl-4-yl]propyl}-acetamide,

*N*-[2-(3',4'-Dimethoxybiphenyl-4-yl)propyl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,

2-(4-Methyl-2,5-dioxoimidazolidin-4-yl)-*N*-[2-(4-quinolin-3-ylphenyl)propyl]-acetamide,

*N*-[5-(4-Fluorophenyl)-2,3-dihydro-1H-inden-2-yl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,

*N*-[5-(1,3-Benzodioxol-5-yl)-2,3-dihydro-1H-inden-2-yl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,

*N*-[5-(3-Methoxyphenyl)-2,3-dihydro-1H-inden-2-yl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,

*N*-{5-[3-(Acetylamino)phenyl]-2,3-dihydro-1H-inden-2-yl}-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,

*N*-[5-(3-Acetylphenyl)-2,3-dihydro-1H-inden-2-yl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,

*N*-[5-(4-Acetylphenyl)-2,3-dihydro-1H-inden-2-yl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,

*N*-[5-(1-Benzothien-2-yl)-2,3-dihydro-1H-inden-2-yl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,

*N*-[5-(3-Cyanophenyl)-2,3-dihydro-1H-inden-2-yl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,

*N*-[5-(4-Cyanophenyl)-2,3-dihydro-1H-inden-2-yl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,

*N*-[5-(4-Fluoro-3-methylphenyl)-2,3-dihydro-1H-inden-2-yl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,

2-(4-Methyl-2,5-dioxoimidazolidin-4-yl)-*N*-{5-[3-(methylthio)phenyl]-2,3-dihydro-1H-inden-2-yl}-acetamide,

*N*-[5-(6-Methoxypyridin-3-yl)-2,3-dihydro-1H-inden-2-yl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,

*N*-[5-(4-Methoxy-3-methylphenyl)-2,3-dihydro-1H-inden-2-yl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,

*N*-[5-(2,3-Dihydro-1-benzofuran-5-yl)-2,3-dihydro-1H-inden-2-yl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,

2-(4-Methyl-2,5-dioxoimidazolidin-4-yl)-*N*-{5-[3-(trifluoromethoxy)phenyl]-2,3-dihydro-1H-inden-2-yl}-acetamide,

*N*-[5-(3,4-Dimethoxyphenyl)-2,3-dihydro-1H-inden-2-yl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,

*N*-[5-(4-Cyano-3-methylphenyl)-2,3-dihydro-1H-inden-2-yl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,

2-(2,5-Dioxoimidazolidin-4-yl)-*N*-(2-{4-[4 (trifluoromethyl)phenoxy]phenyl}ethyl)-acetamide,


2-(2,5-Dioxoimidazolidin-4-yl)-*N*-(2-[4-(4-methoxyphenoxy)phenyl]ethyl)-acetamide,  
2-(2,5-Dioxoimidazolidin-4-yl)-*N*-(2-{4-[4-(trifluoromethoxy)phenoxy]phenyl}ethyl)-acetamide,

*N*-(2-[4-(4-Chlorophenoxy)phenyl]ethyl)-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,  
*N*-(2-[4-(4-Acetylphenoxy)phenyl]ethyl)-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,  
2-(2,5-Dioxoimidazolidin-4-yl)-*N*-(2-[4-(pyridin-3-yloxy)phenyl]ethyl)-acetamide,  
2-(2,5-Dioxoimidazolidin-4-yl)-*N*-(2-{4-[(6-methoxypyridin-3-yl)oxy]phenyl}ethyl)-acetamide,


*N*-(2-[4-(4-Cyanophenoxy)phenyl]ethyl)-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,  
2-(2,5-Dioxoimidazolidin-4-yl)-*N*-(2-[4-(4-methylphenoxy)phenyl]ethyl)-acetamide,  
2-(2,5-Dioxoimidazolidin-4-yl)-*N*-(2-[4-(4-fluorophenoxy)phenyl]ethyl)-acetamide,  
*N*-(2-Biphenyl-4-yl-2-hydroxy-ethyl)-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,  
*N*-(2-(1,1'-Biphenyl-4-yl)-2-methoxyethyl)-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,  
*N*-(2-(1,1'-Biphenyl-4-yl)-ethyl)-2-(2,5-dioxoimidazolidin-4-yl)-*N*-methylacetamide,  
2-(2,5-Dioxoimidazolidin-4-yl)-*N*-(2-(4-phenylethynyl-piperidin-1-yl)ethyl)-acetamide,  
*N*-(2-[(4-Bromobenzyl)oxy]ethyl)-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,  
2-(1,1'-Biphenyl-4-yl)-2-oxoethyl (2,5-dioxoimidazolidin-4-yl)acetate,  
and pharmaceutically acceptable salts and solvates thereof.

12. (Currently amended) A process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as defined in claim 1 which comprises,

(a) when X represents an oxygen atom or a group  $\text{NR}^4$ , reacting a compound of formula




wherein  $X^1$  represents an oxygen atom or a group  $NR^4$  and  $L$ ,  $G^2$  and  $R^4$  are as defined in claim 1, formula (I), with an activated carboxylic acid of formula




wherein  $Y$ ,  $Z^1$ ,  $Z^2$ ,  $R^1$ ,  $R^2$  and  $R^3$  are as defined in claim 1, formula (I); or

(b) when  $X$  represents  $CH_2$ , reacting an activated carboxylic acid of formula (IV) as defined in (a) above with methoxymethylamine or a salt thereof followed by reaction with a Grignard reagent of formula




wherein  $Hal$  represents a halogen atom and  $L$  and  $G^2$  are as defined in claim 1, formula (I); or

(c) when  $X$  represents  $CH_2$ , reacting a compound of formula



wherein  $Y$ ,  $Z^1$ ,  $Z^2$ ,  $R^1$ ,  $R^2$  and  $R^3$  are as defined in claim 1, formula (I), with a compound of formula



wherein  $LG^1$  represents a leaving group and  $L$  and  $G^2$  are as defined in claim 1, formula (I) in the presence of a strong base;

and optionally after (a), (b) or (c) forming a pharmaceutically acceptable salt or solvate.

13. (Currently amended) A pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in ~~any one of claims 1 to 11~~ claim 1 in association with and a pharmaceutically acceptable adjuvant, diluent or carrier.

14. (Currently amended) A process for the preparation of a pharmaceutical composition as ~~claimed in claim 13~~ which comprises mixing a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as defined in ~~any one of claims 1 to 11~~ claim 1 with a pharmaceutically acceptable adjuvant, diluent or carrier.

15-17. (Cancelled)

18. (Currently amended) A method of treating a disease or condition mediated by MMP12 which comprises administering to a patient a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in ~~any one of claims 1 to 11~~ claim 1.

19. (Currently amended) A method of treating an obstructive airways disease which comprises administering to a patient a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in ~~any one of claims 1 to 11~~ claim 1.

20. (New) The method of claim 19, wherein the obstructive airways disease is asthma or chronic obstructive pulmonary disease.